23:09 , Jun 4, 2019 |  BC Extra  |  Company News

Arvinas adds to momentum with Bayer deal for protein degraders

Arvinas is building on its recent momentum by signing Bayer as its fourth pharma partner in a deal announced Tuesday that aims to broaden its pipeline of protein degraders into new indications. The partnership comes...
02:43 , Jun 1, 2019 |  BioCentury  |  Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
21:08 , May 23, 2019 |  BC Innovations  |  Emerging Company Profile

Obsidian: Fine-tuning therapeutic protein expression with approved drugs

Obsidian is building a tool kit of engineered proteins whose expression can be finely tuned with FDA-approved small molecules, and its first application is in boosting the efficacy of cell therapies through a deal with...
21:29 , May 10, 2019 |  BC Extra  |  Company News

Management tracks: Roche veteran Chen joins Everest, CBC Group; plus G1, Rani

Everest Medicines Ltd. (New York, N.Y.) hired Wende Chen as chief commercial officer. He will also serve as an operating partner at CBC Group (formerly C-Bridge Capital), the company's founding investor. Chen was VP of...
19:05 , May 2, 2019 |  BC Innovations  |  Translation in Brief

Continuously capturing cancer cells

A wearable device that captures and isolates circulating tumor cells over the course of a few hours could offer better diagnostic accuracy than single-draw liquid biopsies that screen smaller amounts of blood. A University of...
17:30 , Apr 22, 2019 |  BC Innovations  |  Distillery Therapeutics

Inhibiting the LLGL2-SLC7A5-YKT6 complex for breast cancer

DISEASE CATEGORY: Cancer INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest inhibiting the LLGL2-SLC7A5-YKT6 leucine transporter complex could help treat breast cancer. In patients with estrogen receptor- and progesterone receptor-positive breast cancer,...
21:48 , Apr 2, 2019 |  BC Innovations  |  Distillery Therapeutics

Conbriza bazedoxifene for MS and other demyelinating diseases

DISEASE CATEGORY: Autoimmune disease; neurology INDICATION: Multiple sclerosis (MS); neurology Cell culture and mouse studies suggest Conbriza bazedoxifene could help treat MS and other demyelinating diseases. In oligodendrocyte precursor cells (OPCs) derived from a human...
04:15 , Mar 23, 2019 |  BioCentury  |  Product Development

Baby steps beyond beta amyloid

Companies are taking steps -- baby steps -- to test new targets in pathways such as neuroinflammation and neuroprotection as a means to treat Alzheimer’s disease. The failure of aducanumab won’t be the final nail...
18:40 , Mar 12, 2019 |  BC Extra  |  Financial News

InventisBio raises $70M series C to advance early stage pipeline

InventisBio raised $70 million in a series C round led by Advantech Capital and CMBI, the Chinese biotech announced late Monday. Pudong Innotek and existing investors Lilly Asia Ventures and OrbiMed Asia also participated in...
18:42 , Mar 8, 2019 |  BC Extra  |  Company News

TNBC gets its first targeted agent with Tecentriq approval

The approval of Roche's Tecentriq atezolizumab to treat metastatic triple-negative breast cancer gives almost half of these patients and physicians' their first agent to treat a molecularly defined subgroup of patients with this fast-progressing cancer....